Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Aug;20(8):2590-9.
doi: 10.1245/s10434-013-2887-8. Epub 2013 Mar 17.

Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials

Affiliations
Clinical Trial

Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials

Anne M Wallace et al. Ann Surg Oncol. 2013 Aug.

Abstract

Background: Sentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [(99m)Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to assess the lymphatic mapping performance.

Methods: A total of 13 centers contributed 148 patients with breast cancer. Each patient received [(99m)Tc]tilmanocept and vital blue dye (VBD). Lymph nodes identified intraoperatively as radioactive and/or blue stained were excised and histologically examined. The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [(99m)Tc]tilmanocept.

Results: A total of 13 centers contributed 148 patients who were injected with both agents. Intraoperatively, 207 of 209 nodes detected by VBD were also detected by [(99m)Tc]tilmanocept for a concordance rate of 99.04 % (p < 0.0001). [(99m)Tc]tilmanocept detected a total of 320 nodes, of which 207 (64.7 %) were detected by VBD. [(99m)Tc]Tilmanocept detected at least 1 SLN in more patients (146) than did VBD (131, p < 0.0001). In 129 of 131 patients with ≥1 blue node, all blue nodes were radioactive. Of 33 pathology-positive nodes (18.2 % patient pathology rate), [(99m)Tc]tilmanocept detected 31 of 33, whereas VBD detected only 25 of 33 (p = 0.0312). No pathology-positive SLNs were detected exclusively by VBD. No serious adverse events were attributed to [(99m)Tc]tilmanocept.

Conclusion: [(99m)Tc]Tilmanocept demonstrated success in detecting a SLN while meeting the primary endpoint. Interestingly, [(99m)Tc]tilmanocept was additionally noted to identify more SLNs in more patients. This localization represented a higher number of metastatic breast cancer lymph nodes than that of VBD.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
[99mTc]Tilmanocept is composed of a dextran backbone (black) to which are attached multiple units of mannose (green) and DTPA (blue). The mannose units provide a molecular mechanism by which [99mTc]tilmanocept avidly binds to a receptor specific to recticuloendothelial cells (CD206), and the DTPA units provide a highly stable means to radiolabel tilmanocept with technetium-99m (red). The molecular weight of [99mTc]tilmanocept is approximately 17,000 grams per mole; the molecular diameter is 7.1 nm
Fig. 2
Fig. 2
Lymphoscintigraphy of a 35-year-old woman with carcinoma in situ of the left breast showing 2 intense foci of noted [99mTc]tilmanocept localization within the left axilla. An intradermal injection (0.4 mL, 0.5 mCi, 3.0 nmol) of [99mTc]tilmanocept was administered to the upper left quadrant of the left breast. The SPECT/CT image is a fused sagittal cross section acquired 1 h postinjection, which visualizes a sentinel lymph node (arrow) and the injection site. At 5 h after injection, 3 blue and hot lymph nodes (6,724 cps, 1,477 cps, 167 cps) were detected at surgery and excised. Pathologic examination revealed 1 histologically positive lymph node (blue with 6,700 cps, 1.7 × 1.3 × 0.7 cm) and 2 negative lymph nodes

Similar articles

Cited by

References

    1. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–575. doi: 10.1001/jama.2011.90. - DOI - PMC - PubMed
    1. Gipponi M, Bassetti C, Canavese G, Catturich A, Di Somma C, Vecchio C, et al. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J Surg Oncol. 2004;85:102–111. doi: 10.1002/jso.20022. - DOI - PubMed
    1. Krag DN. Current status of axillary lymph node dissection and sentinel node biopsy in breast cancer. Clin Adv Hematol Oncol. 2010;8:471–473. - PubMed
    1. Rodier J, Janser J. Surgical technical details improving sentinel node identification in breast cancer. Oncol Rep. 1997;4:281–283. - PubMed
    1. Newman LA. Lymphatic mapping and sentinel lymph node biopsy in breast cancer patients: a comprehensive review of variations in performance and technique. J Am Coll Surg. 2004;199:804–816. doi: 10.1016/j.jamcollsurg.2004.05.277. - DOI - PubMed

Publication types

MeSH terms